| Literature DB >> 35114744 |
Shyam Vedantam1, Sunil Amin2, Ben Maher3,4, Saqib Ahmad5, Shanil Kadir6, Saad Khalid Niaz7, Mark Wright4, Nadeem Tehami4.
Abstract
BACKGROUND/AIMS: Cholangiogram interpretation is not used as a key performance indicator (KPI) of endoscopic retrograde cholangiopancreatography (ERCP) training, and national societies recommend different minimum numbers per annum to maintain competence. This study aimed to determine the relationship between correct ERCP cholangiogram interpretation and experience.Entities:
Keywords: Cholangiograms; Endoscopic retrograde cholangiopancreatography; Key performance indicators; Training
Year: 2022 PMID: 35114744 PMCID: PMC9178142 DOI: 10.5946/ce.2021.239
Source DB: PubMed Journal: Clin Endosc ISSN: 2234-2400
Key performance indicators adapted from the ASGE, BSG and ESGE
| KPI category | ASGE recommendation | BSG recommendation | ESGE recommendation |
|---|---|---|---|
|
| |||
| Understanding of indications and risks for ERCP | • >90% frequency that ERCP is done for published indication | • Attachment to at least 1 ERCP unit during training | • Adequate antibiotic prophylaxis before ERCP (>90%) |
| • HPB “orientation” program for interested trainees | |||
| Understanding of periprocedural care | • >98% frequency that appropriate and adequate informed consent is achieved | • Participation in multidisciplinary team at hospital and regular meetings | • Not commented on |
| • >98% frequency that appropriate antibiotics administered if indicated | |||
| Volume and training | • >98% frequency that ERCP is performed by fully trained and credentialed endoscopist | • 75–100 ERCPs per year | • Not commented on |
| • ERCP volume per year is recorded by endoscopist | |||
|
| |||
| Deep cannulation success rate | • >90%–98% success in native papillae without surgically altered anatomy | • >85%–90% successful cannulation in 1st ERCP | • Bile duct cannulation rate (>90%) |
| Stone clearance | • >90% success in CBD stone <1 cm in normal anatomy | • >75%–80% success | • Clearance of CBD stones (>90%) |
| Stent placement for biliary obstruction or extrahepatic stricture | • >90% success in normal anatomy and in those whose obstruction is below the bifurcation | • >80%–85% stent sited and cytology or histology taken when appropriate | • Stent placement in case of biliary obstruction (>90%) |
|
| |||
| Communication | • >98% reporting of specific techniques, particular accessories used, all intended outcomes, reporting of acute adverse events, and contacting patients within 14 days for results of findings | • Participation in multidisciplinary team at hospital and regular meetings | • Not commented on |
| Complications | • Not applicable: rate of post-ERCP pancreatitis (noted as priority indicator, but dependent on type of ERCP performed) | • <6% complication rate for “level 1” procedures | • Safety of ERCP (PEP rate <10%) |
| • <0.2% rate of perforation | |||
| • <1% rate of clinically significant hemorrhage after sphincterotomy or sphincteroplasty | |||
|
| • Not commented on | • Participation in 300–400 ERCP procedures prior to consultant appointment | • Not commented on |
| • Minimum 2 qualified trainers per center both of whom participate in feedback with trainees | |||
| • Weekly multidisciplinary meeting covering benign and malignant diseases | |||
| • Participation in multidisciplinary meetings, hepatobiliary clinics, pre-/post-procedure care | |||
| • Colleagues mentor newly appointed consultants for first 2 years and are available to assist in difficult cases | |||
ASGE, American Society of Gastrointestinal Endoscopy; BSG, British Society of Gastroenterology; ESGE, European Society for Gastrointestinal Endoscopy; ERCP, endoscopic retrograde cholangiopancreatography; HPB, hepatopancreatobiliary; CBD, common bile duct; PEP, post-ERCP pancreatitis.
Fig. 1.Cholangiogram images sent in survey. Images were sent in the open-ended questionnaire. (A) Bile leak 1 (Strasberg type A). (B) Bile leak 2 (Strasberg type B). (C) Hilar stricture 1 (Bismuth type 1). (D) Hilar stricture 2 (Bismuth type 1). (E) Hilar stricture 3 (Bismuth type 2). (F) Distal CBD stricture. (G) Choledocholithiasis 1 (IC; stone size >10 mm). (H) Choledocholithiasis 1 (CC; stone size >10 mm). (I) Choledocholithiasis 2 (IC; stone size <10 mm). (J) Choledocholithiasis 2 (CC; stone size <10 mm). (K) Choledocholithiasis 3 (IC; IHD calculus). (L) Choledocholithiasis 3 (CC; IHD stone). (M) Normal (mildly dilated CBD). CBD, common bile duct; IC, initial cholangiogram; CC, completion/occlusion cholangiogram; IHD, intrahepatic duct.
Accurate interpretation of ERCP cholangiograms: survey results
| Cholangiogram | Trainees ( | Consultants group 1 (number correct) | Consultants group 2 (number correct) |
|---|---|---|---|
| Bile leak 1 (Strasberg type A) | 37 | 43 | 50 |
| Bile leak 2 (Strasberg type B) | 31 | 42 | 50 |
| Hilar stricture 1 (Bismuth type 1) | 30 | 46 | 50 |
| Hilar stricture 2 (Bismuth type 1) | 27 | 44 | 49 |
| Hilar stricture 3 (Bismuth type 2) | 25 | 39 | 48 |
| Distal CBD stricture | 34 | 49 | 49 |
| Choledocholithiasis 1 (IC; stone size >10 mm) | 45 | 50 | 50 |
| Choledocholithiasis 1 (CC; stone size >10 mm) | 46 | 50 | 50 |
| Choledocholithiasis 2 (IC; stone size <10 mm) | 44 | 46 | 50 |
| Choledocholithiasis 2 (CC; stone size <10 mm) | 45 | 45 | 50 |
| Choledocholithiasis 3 (IC; IHD calculus) | 29 | 43 | 45 |
| Choledocholithiasis 3 (CC; IHD stone) | 30 | 42 | 47 |
| Normal (mildly dilated CBD) | 41 | 45 | 50 |
Accurate identification of pathology on ERCP cholangiograms by trainees, graduates, and consultants.
ERCP, endoscopic retrograde cholangiopancreatography; CBD, common bile duct; IC, initial cholangiogram; CC, completion/occlusion cholangiogram; IHD, intrahepatic duct.
Interpretation of ERCP cholangiograms according to the ERCP case volume
| Cholangiogram | Trainees vs. Consultants group 1 | Trainees vs. Consultants group 2 | Consultants group 1 vs. Consultants group 2 | |||
|---|---|---|---|---|---|---|
| OR[ | OR[ | OR[ | ||||
| Bile leak 1 (Strasberg type A) | 0.211 | <0.001 | 0.740 (0.628–0.872) | 0.012 | 0.860 (0.769–0.962) | |
| Bile leak 2 (Strasberg type B) | 0.023 | 0.738 (0.576–0.946) | <0.001 | 0.620 (.499–0.770) | 0.006 | 0.840 (0.744–0.948) |
| Hilar stricture 1 (Bismuth type 1) | <0.001 | 0.652 (0.513–0.830) | <0.001 | 0.600 (0.478–0.752) | 0.117 | |
| Hilar stricture 2 (Bismuth type 1) | <0.001 | 0.614 (0.466–0.808) | <0.001 | 0.551 (0.425–0.714) | 0.112 | |
| Hilar stricture 3 (Bismuth type 2) | 0.006 | 0.641 (0.468–0.877) | <0.001 | 0.521 (0.392–0.691) | 0.015 | 0.813 (0.694–0.951) |
| Distal CBD stricture | <0.001 | 0.694 (0.571–0.843) | <0.001 | 0.694 (0.571–0.843) | 1 | |
| Choledocholithiasis 1 (IC; stone size >10 mm) | 0.056 | 0.056 | 1 | |||
| Choledocholithiasis 1 (CC; stone size >10 mm) | 0.117 | 0.117 | 1 | |||
| Choledocholithiasis 2 (IC; stone size <10 mm) | 0.741 | 0.027 | 0.88 (0.794–0.975) | 0.117 | ||
| Choledocholithiasis 2 (CC; stone size <10 mm) | 1 | 0.056 | 0.056 | |||
| Choledocholithiasis 3 (IC; IHD calculus) | 0.003 | 0.674 (0.519–0.876) | <0.001 | 0.644 (0.500–0.830) | 0.760 | |
| Choledocholithiasis 3 (CC; IHD stone) | 0.013 | 0.714 (0.553–0.923) | <0.001 | 0.638 (0.504–0.809) | 0.200 | |
| Normal (mildly dilated CBD) | 0.388 | 0.003 | 0.820 (0.720–0.934) | 0.056 | ||
ERCP, endoscopic retrograde cholangiopancreatography; OR, odds ratio; CI, confidence interval; CBD, common bile duct; IC, initial cholangiogram; CC, completion/occlusion cholangiogram; IHD, intrahepatic duct.
Mantel-Haenszel odds ratio.